Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

 

EXHIBIT 99.1 

 

SCHEDULE A

 

Funds

 

Date	Number of Shares Bought	Price Per Share($) (1)(2)
10/18/2024	2,410	12.917504(3)
10/21/2024	3,297	12.138269(4)
10/22/2024	1,932	11.861352(5)
10/25/2024	30	11.502906(6)
11/12/2024	3,422	10.620428(7)
11/13/2024	4,095	10.252791(8)
11/14/2024	429	9.642175(9)
12/2/2024	2,358	11.185089(10)
12/3/2024	316	11.208425(11)
12/4/2024	652,042	18.096773 (12)
12/5/2024	387,450	18.101830 (13)
12/6/2024	122,436	18.091399 (14)
12/9/2024	125,322	18.063930(15)
12/10/2024	110,726	18.062610(16)
12/11/2024	119,201	18.073543(17)
12/12/2024	64,707	18.05993 (18)
12/13/2024	88,706	18.058730(19)
12/16/2024	146,406	17.967914(20)
12/17/2024	52,730	17.913389(21)
12/18/2024	77,208	17.905068(22)

 

(1) Excludes commissions and other execution-related costs.

(2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

(3) Reflects a weighted average purchase price of $12.917504 per share, at prices ranging from $12.85 to $13.05 per share.

(4) Reflects a weighted average purchase price of $12.138269 per share, at prices ranging from $11.98 to $12.38 per share.

(5) Reflects a weighted average purchase price of $11.861352 per share, at prices ranging from $11.67 to $12.00 per share.

(6) Reflects a weighted average purchase price of $11.50290 6per share, at prices ranging from $11.47 to $11.54 per share.

(7) Reflects a weighted average purchase price of $10.620428 per share, at prices ranging from $10.43 to $11.00 per share.

(8) Reflects a weighted average purchase price of $10.252791 per share, at prices ranging from $10.04 to $10.52 per share.

(9) Reflects a weighted average purchase price of $9.642175 per share, at prices ranging from $9.59 to $9.72 per share.

(10) Reflects a weighted average purchase price of $11.185089 per share, at prices ranging from $10.82 to $11.58 per share.

(11) Reflects a weighted average purchase price of $11.208425 per share, at prices ranging from $11.10 to $11.31 per share.

(12) Reflects a weighted average purchase price of $18.096773 per share, at prices ranging from $17.97 to $18.15per share.

(13) Reflects a weighted average purchase price of $18.101830 per share, at prices ranging from $18.06 to $18.15 per share.

(14) Reflects a weighted average purchase price of $18.091399 per share, at prices ranging from $18.07 to $18.15 per share.

(15) Reflects a weighted average purchase price of $18.063930 per share, at prices ranging from $18.04 to $18.13 per share.

(16) Reflects a weighted average purchase price of $18.062610 per share, at prices ranging from $18.04 to $18.08 per share.

(17) Reflects a weighted average purchase price of $18.073543 per share, at prices ranging from $18.04 to $18.11 per share.

(18) Reflects a weighted average purchase price of $18.05993 per share, at prices ranging from $18.06 to $18.11 per share.

(19) Reflects a weighted average purchase price of $18.05873 per share, at prices ranging from $$18.05 to $18.10 per share.

(20) Reflects a weighted average purchase price of $17.967914 per share, at prices ranging from $17.86 to $18.07per share.

(21) Reflects a weighted average purchase price of $17.913389 per share, at prices ranging from $17.90 to $17.96 per share.

(22) Reflects a weighted average purchase price of $17.905068 per share, at prices ranging from $17.89 to $19.95 per share.

 

 

 

 

SCHEDULE B

 

Funds

 

Date	Number of Shares Sold	Price Per Share($) (1)(2)
10/25/2024	1	11.540000(3)
11/4/2024	5,168	11.188540(4)
11/5/2024	3,486	11.456947(5)
11/6/2024	2,266	12.254716(6)
11/7/2024	3,401	12.203100(7)
11/8/2024	458	10.724816(8)
11/11/2024	1,589	10.593886(9)
11/14/2024	1	9.885000(10)
11/15/2024	3,819	9.876587 (11)
11/18/2024	3,039	10.421105(12)
11/25/2024	318	10.887562(13)
12/4/2024	2,958	18.115063(14)
12/5/2024	485	18.110865(15)

 

(1) Excludes commissions and other execution-related costs.

(2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

(3) Reflects a weighted average purchase price of $11.540000 per share, at prices ranging from $11.54 to $11.54 per share.

(4) Reflects a weighted average purchase price of $11.188540 per share, at prices ranging from $11.01 to $11.41 per share.

(5) Reflects a weighted average purchase price of $11.456947 per share, at prices ranging from $11.29 to $12.61 per share.

(6) Reflects a weighted average purchase price of $11.502906 per share, at prices ranging from $11.96 to $12.47 per share.

(7) Reflects a weighted average purchase price of $12.254716 per share, at prices ranging from $11.77 to $12.41 per share.

(8) Reflects a weighted average purchase price of $12.203100 per share, at prices ranging from $10.60 to $10.88 per share.

(9) Reflects a weighted average purchase price of $10.593886 per share, at prices ranging from $10.50 to $10.70 per share.

(10) Reflects a weighted average purchase price of $9.885000 per share, at prices ranging from $9.89 to $9.89 per share.

(11) Reflects a weighted average purchase price of $9.876587 per share, at prices ranging from $9.78 to $9.96 per share.

(12) Reflects a weighted average purchase price of $10.421105 per share, at prices ranging from $10.31 to $10.56 per share.

(13) Reflects a weighted average purchase price of $10.887562 per share, at prices ranging from $10.87 to $10.90 per share.

(14) Reflects a weighted average purchase price of $18.115063 per share, at prices ranging from $17.98 to $18.21 per share.

(15) Reflects a weighted average purchase price of $18.110865 per share, at prices ranging from $18.10 to $18.13 per share.

 

 

 

 

EXHIBIT 99.2

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that the statement on Schedule 13D with respect to the Shares of Cross Country Healthcare, Inc. dated as of December 20, 2024 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the previsions of Rule13d-1(k) under the Securities Exchange Act of 1934, as amended.

 

Date:  December 20, 2024

magnetar financial llc

 

By: Magnetar Capital Partners LP, its Sole Member

 

	By:	/s/ Hayley Stein
	Name:	Hayley Stein
	Title:	Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC

 

Date:  December 20, 2024

magnetar capital partners LP

 

By: Supernova Management LLC, its General Partner

 

	By:	/s/ Hayley Stein
	Name:	Hayley Stein
	Title:	Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC

 

Date:  December 20, 2024

supernova management llc

 

	By:	/s/ Hayley Stein
	Name:	Hayley Stein
	Title:	Attorney-in-fact for David J. Snyderman, Manager

 

Date:  December 20, 2024

DAVID J. SNYDERMAN

 

	By:	/s/ Hayley Stein
	Name:	Hayley Stein
	Title:	Attorney-in-fact for David J. Snyderman

 

 

 

 

EXHIBIT 99.3

 

LIMITED POWER OF ATTORNEY

 

Know all by these present, that I, David J. Snyderman, hereby make, constitute and appoint each of Michael Turro, Karl Wachter and Hayley Stein, or any of them acting individually, and with full power of substitution, as my true and lawful attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in my capacity as Manager or in other capacities of Supernova Management LLC, a Delaware limited liability company, and each of its affiliates or entities advised or controlled by me or Supernova Management LLC, all documents, certificates, instruments, statements, filings and agreements (“documents”) to be filed with or delivered to the United States Securities and Exchange Commission (the “SEC”) pursuant to the Securities and Exchange Act of 1934, as amended (the “Act”), and the rules and regulations promulgated thereunder, including, without limitation, all documents relating to the beneficial ownership of securities required to be filed with the SEC pursuant to Section 13(d) or Section 16(a) of the Act, including, without limitation: (a) any acquisition statements on Schedule 13D or Schedule 13G and any amendments thereto, (b) any joint filing agreements pursuant to Rule 13d-1(k) under the Act, and (c) any initial statements of, or statements of changes in, beneficial ownership of securities on Form 3, Form 4 or Form 5.

 

All past acts of the attorney-in-fact in furtherance of the foregoing are hereby ratified and confirmed.

 

This Power of Attorney shall remain in full force and effect until the earlier of it being (a) revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (b) superseded by a new power of attorney regarding the purposes outlined herein as of a later date.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 22 day of December, 2022.

 

	/s/ David J. Snyderman
	David J. Snyderman

 

 

 

---